Proficiency testing in immunohistochemistry—experiences from Nordic Immunohistochemical Quality Control (NordiQC)

Despite extensive use of immunohistochemistry (IHC) for decades, lack of standardization remains a major problem, even aggravated in the era of targeted therapy. Nordic Immunohistochemical Quality Control (NordiQC) is an international academic proficiency testing (PT) program established in 2003 primarily aimed at assessing the analytical phases of the laboratory IHC quality. About 700 laboratories from 80 countries are currently participating. More than 30,000 IHC slides have been evaluated during 2003–2015. Overall, about 20 % of the staining results in the breast cancer IHC module and about 30 % in the general module have been assessed as insufficient for diagnostic use. The most common causes for insufficient results are less successful antibodies (poor and less robust antibodies, poorly calibrated ready-to-use (RTU) products, and stainer platform-dependent antibodies; 17 %), insufficiently calibrated antibody dilutions (20 %), insufficient or erroneous epitope retrieval (27 %), less sensitive visualization systems (19 %), and other (heat- and proteolysis-induced impaired morphology, endogenous biotin reaction, drying out phenomena, stainer platform-dependant protocol issues; 17 %). Approximately, 90 % of the insufficient results are characterized by either a too weak or false negative staining, whereas in the remaining 10 %, a poor signal-to-noise ratio or false positive staining is seen. Individually tailored recommendations for protocol optimization and identification of best tissue controls to ensure appropriate calibration of the IHC assay have for many markers improved IHC staining as well as inter-laboratory consistency of the IHC results. RTUs will not always provide an optimal result and data sheets frequently misguide the laboratories hampering the improvement in IHC quality. The overall data generated by NordiQC during 12 years indicates that continuous PT is valuable and necessary. Detailed description of the results of the NordiQC programme is available on www.nordiqc.org and summarized in this paper.

[1]  W. Travis WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[2]  William J. Howat,et al.  Antibody validation of immunohistochemistry for biomarker discovery: Recommendations of a consortium of academic and pharmaceutical based histopathology researchers , 2014, Methods.

[3]  Michael Grunkin,et al.  Image analysis of breast cancer HER2 protein expression used in assessment of staining quality , 2014 .

[4]  Clive R Taylor,et al.  Recommendations for Improved Standardization of Immunohistochemistry , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[6]  Søren Nielsen,et al.  Digital image analysis of membrane connectivity is a robust measure of HER2 immunostains , 2012, Breast Cancer Research and Treatment.

[7]  Clive R. Taylor,et al.  Standardization of Negative Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Panel , 2014, Applied immunohistochemistry & molecular morphology : AIMM.

[8]  C. Lindskog,et al.  Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers , 2014, Molecular oncology.

[9]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Clive R. Taylor,et al.  Standardization of Positive Controls in Diagnostic Immunohistochemistry: Recommendations From the International Ad Hoc Expert Committee , 2015, Applied immunohistochemistry & molecular morphology : AIMM.

[11]  M. Vyberg,et al.  Demonstration of CDX2 is Highly Antibody Dependant , 2012, Applied immunohistochemistry & molecular morphology : AIMM.

[12]  David R. Jones,et al.  Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis , 2015, The American journal of surgical pathology.

[13]  B. Gilks,et al.  Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. , 2010, American journal of clinical pathology.

[14]  J. Papadimitriou,et al.  The total test approach to standardization of immunohistochemistry. , 2009, Archives of pathology & laboratory medicine.

[15]  J. Rüschoff,et al.  Proficiency testing of immunohistochemical biomarker assays in breast cancer , 2008, Virchows Archiv.

[16]  Clive R Taylor,et al.  Consensus Recommendations on Estrogen Receptor Testing in Breast Cancer By Immunohistochemistry , 2008, Applied immunohistochemistry & molecular morphology : AIMM.

[17]  Richard Berendt,et al.  Inappropriate calibration and optimisation of pan-keratin (pan-CK) and low molecular weight keratin (LMWCK) immunohistochemistry tests: Canadian Immunohistochemistry Quality Control (CIQC) experience , 2011, Journal of Clinical Pathology.

[18]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.